LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 17

Search options

  1. Article ; Online: Vulnerabilities in kidney transplant recipients with COVID-19: a single center experience.

    Meziyerh, Soufian / van der Helm, Danny / de Vries, Aiko P J

    Transplant international : official journal of the European Society for Organ Transplantation

    2020  Volume 33, Issue 11, Page(s) 1557–1561

    MeSH term(s) Adult ; Aged ; COVID-19/etiology ; COVID-19/mortality ; COVID-19/therapy ; Case-Control Studies ; Female ; Humans ; Kidney Failure, Chronic/mortality ; Kidney Failure, Chronic/surgery ; Kidney Transplantation ; Male ; Middle Aged ; Postoperative Complications/mortality ; Postoperative Complications/therapy ; Risk Factors ; Survival Analysis ; United States/epidemiology
    Keywords covid19
    Language English
    Publishing date 2020-08-26
    Publishing country Switzerland
    Document type Letter
    ZDB-ID 639435-8
    ISSN 1432-2277 ; 0934-0874
    ISSN (online) 1432-2277
    ISSN 0934-0874
    DOI 10.1111/tri.13714
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Tacrolimus and Mycophenolic Acid Exposure Are Associated with Biopsy-Proven Acute Rejection: A Study to Provide Evidence for Longer-Term Target Ranges.

    Meziyerh, Soufian / van Gelder, Teun / Kers, Jesper / van der Helm, Danny / van der Boog, Paul J M / de Fijter, Johan W / Moes, Dirk Jan A R / de Vries, Aiko P J

    Clinical pharmacology and therapeutics

    2023  Volume 114, Issue 1, Page(s) 192–200

    Abstract: Evidence to define target ranges for tacrolimus (Tac) and mycophenolic acid (MPA) exposure after the first year of kidney transplantation is limited. We investigated the association of measurements at 1 year and repeated measurements of real-world Tac- ... ...

    Abstract Evidence to define target ranges for tacrolimus (Tac) and mycophenolic acid (MPA) exposure after the first year of kidney transplantation is limited. We investigated the association of measurements at 1 year and repeated measurements of real-world Tac-trough levels (C
    MeSH term(s) Humans ; Tacrolimus/adverse effects ; Mycophenolic Acid/adverse effects ; Immunosuppressive Agents/adverse effects ; Kidney Transplantation/adverse effects ; Graft Rejection/prevention & control
    Chemical Substances Tacrolimus (WM0HAQ4WNM) ; Mycophenolic Acid (HU9DX48N0T) ; Immunosuppressive Agents
    Language English
    Publishing date 2023-05-10
    Publishing country United States
    Document type Journal Article
    ZDB-ID 123793-7
    ISSN 1532-6535 ; 0009-9236
    ISSN (online) 1532-6535
    ISSN 0009-9236
    DOI 10.1002/cpt.2915
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Primary sclerosing cholangitis and other risk factors for post-transplant lymphoproliferative disease after liver transplantation in adults.

    Ruijter, Bastian N / Tushuizen, Maarten E / van der Helm, Danny / Hew, Mitchel / Reeven, Marjolein / Vossen, Ann C T M / Metselaar, Herold J / Alwayn, Ian P J / Dubbeld, Jeroen / Polak, Wojciech G / van Hoek, Bart

    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society

    2023  

    Abstract: Post-transplant lymphoproliferative disease (PTLD) is a rare but serious complication of liver transplantation (LT) with morbidity and mortality. The risk factors for PTLD in adults are ill-defined. This study aimed to assess the risk factors for PTLD ... ...

    Abstract Post-transplant lymphoproliferative disease (PTLD) is a rare but serious complication of liver transplantation (LT) with morbidity and mortality. The risk factors for PTLD in adults are ill-defined. This study aimed to assess the risk factors for PTLD after LT in adults. All adult LT recipients between 1986 and 2016 from 2 centers in the Netherlands were included, with follow-up until 2020. PTLD was diagnosed according to the World Health Organization (WHO) classification. Potential risk factors for PTLD were assessed using multivariate Cox regression analysis. A total of 1281 patients were included, of whom 29 (2.3%) developed PTLD. Results show that independent risk factors for PTLD after LT in adults were no Epstein-Barr virus load monitoring strategy, primary sclerosing cholangitis as an indication for LT, era (historic era linked to more intense long-term immunosuppression), and Epstein-Barr virus-seronegative recipient. No other independent risk factors were identified in this study. Of the 207 patients with primary sclerosing cholangitis as an indication for LT, 13 (6.3%) developed PTLD versus 16 out of 1074 (1.5%) patients with other underlying liver diseases (log-rank p <0.001). The yearly PTLD incidence was higher in the first year than in the later years after LT (2.4%/y vs. 0.6%/y) for primary sclerosing cholangitis, but not for other indications (0.16%/y). In Epstein-Barr virus-seronegative recipients PTLD occurred earlier after LT, while in 97% of seropositive recipients it could occur very late after LT.
    Language English
    Publishing date 2023-09-13
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2006866-9
    ISSN 1527-6473 ; 1527-6465
    ISSN (online) 1527-6473
    ISSN 1527-6465
    DOI 10.1097/LVT.0000000000000256
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Epstein-Barr Viral Load Monitoring Strategy and the Risk for Posttransplant Lymphoproliferative Disease in Adult Liver Transplantation : A Cohort Study.

    Ruijter, Bastian N / Wolterbeek, Ron / Hew, Mitchell / van Reeven, Marjolein / van der Helm, Danny / Dubbeld, Jeroen / Tushuizen, Maarten E / Metselaar, Herold / Vossen, Ann C T M / van Hoek, Bart

    Annals of internal medicine

    2023  Volume 176, Issue 2, Page(s) 174–181

    Abstract: Background: Primary infection with or reactivation of Epstein-Barr virus (EBV) can occur after liver transplant (LT) and can lead to posttransplant lymphoproliferative disease (PTLD). In pediatric LT, an EBV-DNA viral load (EBV VL) monitoring strategy, ... ...

    Abstract Background: Primary infection with or reactivation of Epstein-Barr virus (EBV) can occur after liver transplant (LT) and can lead to posttransplant lymphoproliferative disease (PTLD). In pediatric LT, an EBV-DNA viral load (EBV VL) monitoring strategy, including the reduction of immunosuppression, has led to a lower incidence of PTLD. For adult LT recipients with less primary infection and more EBV reactivation, it is unknown whether this strategy is effective.
    Objective: To examine the effect of an EBV VL monitoring strategy on the incidence of PTLD after LT in adults.
    Design: Cohort study.
    Setting: Two university medical centers in the Netherlands.
    Patients: Adult recipients of first LT in Leiden between September 2003 and January 2017 with an EBV VL monitoring strategy formed the monitoring group (M1), recipients of first LT in Rotterdam between January 2003 and January 2017 without such a strategy formed the contemporary control group (C1), and those who had transplants in Leiden between September 1992 and September 2003 or Rotterdam between 1986 and January 2003 formed the historical control groups (M0 and C0, respectively).
    Measurements: Influence of EBV VL monitoring on incidence of PTLD.
    Results: After inverse probability of treatment weighting of the 4 groups to achieve a balance among the groups for important patient characteristics, differences within hospitals between the historical and recent era in cumulative incidences-expressed as the number of events per 1000 patients measured at 5-, 10-, and 15-year follow-up-showed fewer events in the contemporary era in both centers. This difference was considerably larger in the monitoring center, whereas the 95% CI included the null value of 0 for point estimates.
    Limitation: Retrospective, low statistical power, and incompletely balanced groups, and non-EBV PTLD cannot be prevented.
    Conclusion: Monitoring EBV VL may reduce PTLD incidence after LT in adults; larger studies are warranted.
    Primary funding source: None.
    MeSH term(s) Humans ; Child ; Adult ; Herpesvirus 4, Human/genetics ; Epstein-Barr Virus Infections/epidemiology ; Cohort Studies ; Liver Transplantation/adverse effects ; Retrospective Studies ; Viral Load ; Lymphoproliferative Disorders/epidemiology ; Lymphoproliferative Disorders/etiology ; Lymphoproliferative Disorders/prevention & control ; DNA, Viral
    Chemical Substances DNA, Viral
    Language English
    Publishing date 2023-01-17
    Publishing country United States
    Document type Journal Article
    ZDB-ID 336-0
    ISSN 1539-3704 ; 0003-4819
    ISSN (online) 1539-3704
    ISSN 0003-4819
    DOI 10.7326/M22-0364
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Mycophenolic Acid Exposure Determines Antibody Formation Following SARS-CoV-2 Vaccination in Kidney Transplant Recipients: A Nested Cohort Study.

    Meziyerh, Soufian / Bouwmans, Pim / van Gelder, Teun / van der Helm, Danny / Messchendorp, Lianne / van der Boog, Paul J M / de Fijter, Johan W / Moes, Dirk Jan A R / de Vries, Aiko P J

    Clinical pharmacology and therapeutics

    2023  Volume 114, Issue 1, Page(s) 118–126

    Abstract: Despite (repeated) boosting, kidney transplant recipients (KTRs) may remain at increased risk of severe COVID-19 since a substantial number of individuals remain seronegative or with low antibody titers. In particular, mycophenolic acid use has been ... ...

    Abstract Despite (repeated) boosting, kidney transplant recipients (KTRs) may remain at increased risk of severe COVID-19 since a substantial number of individuals remain seronegative or with low antibody titers. In particular, mycophenolic acid use has been shown to affect antibody formation negatively and may be an important modifiable risk factor. We investigated the exposure-response relationship between mycophenolic acid 12-hour area under the curve (AUC
    MeSH term(s) Humans ; Antibodies ; Antibody Formation ; Cohort Studies ; COVID-19/prevention & control ; COVID-19 Vaccines/adverse effects ; Kidney Transplantation/adverse effects ; Mycophenolic Acid/adverse effects ; SARS-CoV-2 ; Vaccination
    Chemical Substances Antibodies ; COVID-19 Vaccines ; Mycophenolic Acid (HU9DX48N0T)
    Language English
    Publishing date 2023-03-14
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 123793-7
    ISSN 1532-6535 ; 0009-9236
    ISSN (online) 1532-6535
    ISSN 0009-9236
    DOI 10.1002/cpt.2872
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Randomized Trial of Ciclosporin with 2-h Monitoring vs. Tacrolimus with Trough Monitoring in Liver Transplantation: DELTA Study.

    Ruijter, Bastian N / Inderson, Akin / van den Berg, Aad P / Metselaar, Herold J / Dubbeld, Jeroen / Tushuizen, Maarten E / Porte, Robert J / Polak, Wojciech / van der Helm, Danny / van Reeven, Marjolein / Rodriguez-Girondo, Mar / van Hoek, Bart

    Journal of clinical and translational hepatology

    2023  Volume 11, Issue 4, Page(s) 839–849

    Abstract: Background and aims: Previous trials comparing cyclosporine and tacrolimus after liver transplantation (LT) showed conflicting results. Most used trough monitoring for cyclosporine (C0), leading to less accurate dosing than with 2-h monitoring (C2). ... ...

    Abstract Background and aims: Previous trials comparing cyclosporine and tacrolimus after liver transplantation (LT) showed conflicting results. Most used trough monitoring for cyclosporine (C0), leading to less accurate dosing than with 2-h monitoring (C2). Only one larger trial compared C2 with tacrolimus based on trough level (T0) after LT, with similar treated biopsy-proven acute rejection (tBPAR) and graft loss, while a smaller trial had less tBPAR with C2 compared to T0. Therefore, it is still unclear which calcineurin inhibitor is preferred after LT. We aimed to demonstrate superior efficacy (tBPAR), tolerability, and safety of C2 or T0 after first LT.
    Methods: Patients after first LT were randomized to C2 or T0. tBPAR, patient- and graft survival, safety and tolerability were the main endpoints, with analysis by Fisher test, Kaplan-Meier survival analysis and log-rank test.
    Results: In intention-to-treat analysis 84 patients on C2 and 85 on T0 were included. Cumulative incidence of tBPAR C2 vs. T0 was 17.7% vs. 8.4% at 3 months (
    Conclusions: In the first year after LT immunosuppression with T0 leads to less tBPAR and better patient-/re-transplant-free survival as compared to C2.
    Language English
    Publishing date 2023-03-07
    Publishing country United States
    Document type Journal Article
    ZDB-ID 3019822-7
    ISSN 2310-8819 ; 2225-0719
    ISSN (online) 2310-8819
    ISSN 2225-0719
    DOI 10.14218/JCTH.2022.00348
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Oncofetal Protein CRIPTO Is Involved in Wound Healing and Fibrogenesis in the Regenerating Liver and Is Associated with the Initial Stages of Cardiac Fibrosis.

    Karkampouna, Sofia / van der Helm, Danny / Scarpa, Mario / van Hoek, Bart / Verspaget, Hein W / Goumans, Marie-Jose / Coenraad, Minneke J / Kruithof, Boudewijn P T / Kruithof-de Julio, Marianna

    Cells

    2021  Volume 10, Issue 12

    Abstract: Oncofetal protein, CRIPTO, is silenced during homeostatic postnatal life and often re-expressed in different neoplastic processes, such as hepatocellular carcinoma. Given the reactivation of CRIPTO in pathological conditions reported in various adult ... ...

    Abstract Oncofetal protein, CRIPTO, is silenced during homeostatic postnatal life and often re-expressed in different neoplastic processes, such as hepatocellular carcinoma. Given the reactivation of CRIPTO in pathological conditions reported in various adult tissues, the aim of this study was to explore whether CRIPTO is expressed during liver fibrogenesis and whether this is related to the disease severity and pathogenesis of fibrogenesis. Furthermore, we aimed to identify the impact of CRIPTO expression on fibrogenesis in organs with high versus low regenerative capacity, represented by murine liver fibrogenesis and adult murine heart fibrogenesis. Circulating CRIPTO levels were measured in plasma samples of patients with cirrhosis registered at the waitlist for liver transplantation (LT) and 1 year after LT. The expression of CRIPTO and fibrotic markers (αSMA, collagen type I) was determined in human liver tissues of patients with cirrhosis (on a basis of viral hepatitis or alcoholic disease), in cardiac tissue samples of patients with end-stage heart failure, and in mice with experimental liver and heart fibrosis using immuno-histochemical stainings and qPCR. Mouse models with experimental chronic liver fibrosis, induced with multiple shots of carbon tetrachloride (CCl
    MeSH term(s) Adenoviridae/metabolism ; Animals ; Cell Proliferation ; Collagen/metabolism ; Disease Models, Animal ; End Stage Liver Disease/metabolism ; Epidermal Growth Factor/metabolism ; Fibrosis ; GPI-Linked Proteins/metabolism ; Hepatocytes/metabolism ; Hepatocytes/pathology ; Intercellular Signaling Peptides and Proteins/metabolism ; Ligands ; Liver Cirrhosis/metabolism ; Liver Cirrhosis/pathology ; Liver Regeneration ; Male ; Membrane Glycoproteins/metabolism ; Mice, Inbred C57BL ; Myocardium/metabolism ; Myocardium/pathology ; Neoplasm Proteins/metabolism ; Up-Regulation ; Wound Healing ; Mice
    Chemical Substances GPI-Linked Proteins ; Intercellular Signaling Peptides and Proteins ; Ligands ; Membrane Glycoproteins ; Neoplasm Proteins ; TDGF1 protein, human ; Tdgf1 protein, mouse ; Epidermal Growth Factor (62229-50-9) ; Collagen (9007-34-5)
    Language English
    Publishing date 2021-11-26
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 2661518-6
    ISSN 2073-4409 ; 2073-4409
    ISSN (online) 2073-4409
    ISSN 2073-4409
    DOI 10.3390/cells10123325
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Selected liver grafts from donation after circulatory death can be safely used for retransplantation - a multicenter retrospective study.

    van Reeven, Marjolein / van Leeuwen, Otto B / van der Helm, Danny / Darwish Murad, Sarwa / van den Berg, Aad P / van Hoek, Bart / Alwayn, Ian P J / Polak, Wojciech G / Porte, Robert J

    Transplant international : official journal of the European Society for Organ Transplantation

    2020  Volume 33, Issue 6, Page(s) 667–674

    Abstract: Due to the growing number of liver transplantations (LTs), there is an increasing number of patients requiring retransplantation (reLT). Data on the use of grafts from extended criteria donors (ECD), especially donation after circulatory death (DCD), for ...

    Abstract Due to the growing number of liver transplantations (LTs), there is an increasing number of patients requiring retransplantation (reLT). Data on the use of grafts from extended criteria donors (ECD), especially donation after circulatory death (DCD), for reLT are lacking. We aimed to assess the outcome of patients undergoing reLT using a DCD graft in the Netherlands between 2001 and July 2018. Propensity score matching was used to match each DCD-reLT with three DBD-reLT cases. Primary outcomes were patient and graft survival. Secondary outcome was the incidence of biliary complications, especially nonanastomotic strictures (NAS). 21 DCD-reLT were compared with 63 matched DBD-reLTs. Donors in the DCD-reLT group had a significantly lower BMI (22.4 vs. 24.7 kg/m
    MeSH term(s) Brain Death ; Death ; Graft Survival ; Humans ; Liver ; Netherlands ; Reoperation ; Retrospective Studies ; Tissue Donors ; Tissue and Organ Procurement
    Language English
    Publishing date 2020-03-09
    Publishing country England
    Document type Journal Article ; Multicenter Study
    ZDB-ID 639435-8
    ISSN 1432-2277 ; 0934-0874
    ISSN (online) 1432-2277
    ISSN 0934-0874
    DOI 10.1111/tri.13596
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Local but not systemic administration of mesenchymal stromal cells ameliorates fibrogenesis in regenerating livers.

    van der Helm, Danny / Barnhoorn, Marieke C / de Jonge-Muller, Eveline S M / Molendijk, Ilse / Hawinkels, Luuk J A C / Coenraad, Minneke J / van Hoek, Bart / Verspaget, Hein W

    Journal of cellular and molecular medicine

    2019  Volume 23, Issue 9, Page(s) 6238–6250

    Abstract: Chronic liver injury leads to the accumulation of myofibroblasts resulting in increased collagen deposition and hepatic fibrogenesis. Treatments specifically targeting fibrogenesis are not yet available. Mesenchymal stromal cells (MSCs) are fibroblast- ... ...

    Abstract Chronic liver injury leads to the accumulation of myofibroblasts resulting in increased collagen deposition and hepatic fibrogenesis. Treatments specifically targeting fibrogenesis are not yet available. Mesenchymal stromal cells (MSCs) are fibroblast-like stromal (stem) cells, which stimulate tissue regeneration and modulate immune responses. In the present study we assessed whether liver fibrosis and cirrhosis can be reversed by treatment with MSCs or fibroblasts concomitant to partial hepatectomy (pHx)-induced liver regeneration. After carbon tetrachloride-induced fibrosis and cirrhosis, mice underwent a pHx and received either systemically or locally MSCs in one of the two remaining fibrotic/cirrhotic liver lobes. Eight days after treatment, liver fibrogenesis was evaluated by Sirius-red staining for collagen deposition. A significant reduction of collagen content in the locally treated lobes of the regenerated fibrotic and cirrhotic livers was observed in mice that received high dose MSCs. In the non-MSC-treated counterpart liver lobes no changes in collagen deposition were observed. Local fibroblast administration or intravenous administration of MSCs did not ameliorate fibrosis. To conclude, local administration of MSCs after pHx, in contrast to fibroblasts, results in a dose-dependent on-site reduction of collagen deposition in mouse models for liver fibrosis and cirrhosis.
    MeSH term(s) Animals ; Carbon Tetrachloride/toxicity ; Collagen/metabolism ; Disease Models, Animal ; Fibroblasts/transplantation ; Fibrosis/chemically induced ; Fibrosis/genetics ; Fibrosis/pathology ; Fibrosis/therapy ; Hepatic Stellate Cells/transplantation ; Humans ; Liver/growth & development ; Liver/pathology ; Liver Cirrhosis/chemically induced ; Liver Cirrhosis/genetics ; Liver Cirrhosis/pathology ; Liver Cirrhosis/therapy ; Liver Regeneration/genetics ; Mesenchymal Stem Cell Transplantation ; Mesenchymal Stem Cells/cytology ; Mice
    Chemical Substances Collagen (9007-34-5) ; Carbon Tetrachloride (CL2T97X0V0)
    Language English
    Publishing date 2019-06-27
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2074559-X
    ISSN 1582-4934 ; 1582-4934 ; 1582-1838
    ISSN (online) 1582-4934
    ISSN 1582-4934 ; 1582-1838
    DOI 10.1111/jcmm.14508
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top